Overview

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Carboplatin
Cisplatin
Gemcitabine